Kodiak Sciences Inc. reports positive Phase 3 results for Zenkuda in diabetic retinopathy, showing strong efficacy and safety, reducing vision risks, and supporting plans to submit a biologics license application.
Zenkuda Meets Phase 3 Endpoint With Strong Efficacy
Kodiak Sciences says its late-stage GLOW2 trial meets the primary endpoint, showing significant improvement in patients with diabetic retinopathy. The study includes a broad population, including those with proliferative disease and mild macular edema.
The company reports that 62.5% of treated patients achieve a two-step improvement on the Diabetic Retinopathy Severity Scale. In comparison, 3.3% of patients in the control group reached the same outcome.
“This level of separation highlights the potential of Zenkuda to change treatment outcomes,” the company says in a statement. The findings are consistent with results from the earlier GLOW1 Phase 3 study.
Zenkuda also reduces the risk of sight-threatening complications by 85% through Week 48. These complications include worsening proliferative disease and center-involving macular edema.
Additionally, 13.7% of treated patients achieve a three-step improvement, while none in the control group reach that level. Researchers say the data confirm both efficacy and consistency across trials.
Extended Dosing and Safety Profile Stand Out
Kodiak Sciences highlights Zenkuda’s dosing schedule as a key advantage. After initial loading doses, patients transition to injections spaced up to six months apart.
Experts say frequent injections are a major barrier to current retinal treatments. “Reducing treatment burden could significantly improve patient adherence,” a clinical researcher involved in the study says.
All patients in the trial reached six-month dosing intervals by the end of the study. The company says this durability may improve real-world outcomes.
The safety profile remains favorable throughout the trial. Researchers report low rates of ocular side effects, with no cases of intraocular inflammation or retinal vasculitis.
“These safety results are encouraging, especially for long-term treatment,” the researcher adds.
Data Supports Regulatory Path and Broader Use
Zenkuda is built on an antibody biopolymer conjugate platform designed for sustained drug delivery. The company says this allows longer-lasting effects in ocular tissues compared with existing therapies.
The trial includes patients using GLP-1 therapies, reflecting real-world conditions. Outcomes remain consistent regardless of GLP-1 use, suggesting broader applicability across diabetic populations.
Kodiak Sciences is developing additional treatments using the same platform, targeting retinal vascular and inflammatory diseases. More Phase 3 results are expected in the coming months.
Diabetic retinopathy affects millions worldwide and can lead to vision loss if untreated. Current therapies, including anti-VEGF treatments, require frequent dosing, limiting their use in early stages.
Industry analysts say durable therapies like Zenkuda could address a major gap in care. “Longer dosing intervals may shift how early and consistently patients receive treatment,” an independent healthcare analyst says.
The GLOW2 results strengthen Kodiak’s clinical package as it prepares for regulatory submission. The company plans to move forward with a biologics license application based on combined Phase 3 data.
Visit Healthcare 360 Magazine For The Most Recent Information.
